

## Preliminary program

Self-paced learning package: Available from Friday 17 January 2025

Topic and presenters		Learning objectives
Part 1	<p><b>Use of laboratory data in clinical practice</b></p> <p><b>Professor Jeff Hughes</b></p>	<ul style="list-style-type: none"> <li>Describe laboratory test data used to evaluate the appropriateness of drug therapy</li> <li>Assess therapeutic outcomes and disease progression using laboratory test data</li> <li>Describe laboratory test data used in the assessment and prevention of adverse drug reactions</li> </ul>
	<p><b>Sodium</b></p> <p><b>Karl Winckel</b></p>	<ul style="list-style-type: none"> <li>Understand the presentation, causes and risks associated with hypo/hypernatraemia</li> <li>Understand management options for hyponatraemia in terms of:                             <ul style="list-style-type: none"> <li>Appropriate treatments including cessation of causative drugs</li> <li>Benefits of treatment</li> <li>Risks of treatment or under-treatment</li> </ul> </li> </ul>
	<p><b>Potassium</b></p> <p><b>Karl Winckel</b></p>	<ul style="list-style-type: none"> <li>Understand the presentation, causes and risks associated with common serum potassium disturbances</li> <li>Understand management options for serum potassium in terms of:                             <ul style="list-style-type: none"> <li>Appropriate treatments including cessation of causative drugs</li> <li>Benefits of treatment</li> <li>Risks of treatment or under-treatment</li> </ul> </li> </ul>
	<p><b>Magnesium</b></p> <p><b>Professor Jeff Hughes</b></p>	<ul style="list-style-type: none"> <li>Understand the presentation, causes and risks associated with hypomagnesemia</li> <li>Understand management options for hypomagnesemia in terms of:                             <ul style="list-style-type: none"> <li>Appropriate treatments including cessation of causative drugs</li> <li>Benefits of treatment</li> <li>Risks of treatment or under-treatment</li> </ul> </li> </ul>

Part 2	<b>Acid-base balance</b> <b>Professor Jeff Hughes</b>	<ul style="list-style-type: none"> <li>Describe laboratory test data used to evaluate the appropriateness of drug therapy</li> <li>Assess therapeutic outcomes and disease progression using laboratory test data</li> <li>Describe laboratory test data used in the assessment and prevention of adverse drug reactions</li> </ul>
	<b>Urea and creatinine</b> <b>Bhavini Patel</b>	<ul style="list-style-type: none"> <li>Identify people at greatest risk of kidney disease</li> <li>Explain the diagnosis and classification of acute and chronic kidney disease</li> <li>Discuss the advantages and limitations of different markers of kidney function</li> </ul>
	<b>Calcium and phosphate</b> <b>Bhavini Patel</b>	<ul style="list-style-type: none"> <li>Evaluate the normal ranges for calcium and phosphate and their variation within the normal range</li> <li>Describe the measurement and interpretation of these laboratory tests, and the influence of commonly used drug therapy on them</li> <li>Describe the relevance of further laboratory test investigations</li> <li>Describe monitoring requirements for a patient with kidney disease</li> </ul>
	<b>Liver function tests</b> <b>Professor Jeff Hughes</b>	<ul style="list-style-type: none"> <li>Describe laboratory test data used to evaluate the appropriateness of drug therapy</li> <li>Assess therapeutic outcomes and disease progression using laboratory test data</li> <li>Describe laboratory test data used in the assessment and prevention of adverse drug reactions</li> </ul>
Part 3	<b>Troponin and creatinine kinase</b> <b>Karl Winckel</b>	<ul style="list-style-type: none"> <li>Understand what troponin and creatinine kinase (CK) are</li> <li>Understand the role and limitations of troponin and CK in the diagnosis and management of acute coronary syndrome (ACS)</li> </ul>
	<b>Coagulation lab tests</b> <b>Karl Winckel</b>	<ul style="list-style-type: none"> <li>Understand the simplified coagulation cascade</li> <li>Why different coagulation test results are used for different anticoagulants</li> <li>Discuss the limitations of coagulation tests in the clinical use of DOACs</li> </ul>

	<p><b>Haemoglobin, red cells, and iron studies</b> <b>Bhavini Patel</b></p>	<ul style="list-style-type: none"> <li>• Explain the relevance and significance of derangements of individual components of full blood count and iron study laboratory tests</li> <li>• Distinguish between a picture of iron deficiency anaemia and other types of common anaemia based on laboratory tests</li> </ul>
	<p><b>White cells and acute phase reactants</b> <b>Professor Jeff Hughes</b></p>	<ul style="list-style-type: none"> <li>• List multiple reasons for elevation and reduction of white cells and acute phase reactants</li> <li>• Apply this knowledge of the tests discussed to various clinical situations</li> </ul>
	<p><b>Natriuretic peptide</b> <b>Karl Winckel</b></p>	<ul style="list-style-type: none"> <li>• Explain the role of natriuretic peptides in the diagnosis and management of heart failure</li> </ul>

## Program

Live seminar: Saturday 1 March 2025

*All times listed are in AEDT*

Time (AEDT)	Session
0920-0930	Online login available
0930-0940	Welcome, introduction, housekeeping
0940-1030	<p><b>Perfect partners: why certain lab tests are partnered</b></p> <ul style="list-style-type: none"> <li>Describe why certain laboratory tests are partnered</li> <li>Describe the relationship between various laboratory tests</li> <li>Identify laboratory test results that are dependent on others</li> <li>Identify additional laboratory tests that are required to accurately interpret data</li> <li>Apply partnered laboratory test results to clinical scenarios</li> </ul>
1030-1130	<p><b>Case session: Liver function tests</b></p> <ul style="list-style-type: none"> <li>Describe laboratory test data used to evaluate the appropriateness of drug therapy</li> <li>Assess therapeutic outcomes and disease progression using laboratory test data</li> <li>Describe laboratory test data used to in the assessment and prevention of adverse drug reactions</li> <li>Apply knowledge of the above to clinical scenarios involving patients with liver impairment</li> </ul>
1130-1150	BREAK
1150-1305	<p><b>Case session: Kidney disease</b></p> <ul style="list-style-type: none"> <li>Use laboratory data to assess the appropriateness of drug therapy for clinical case scenarios</li> <li>Develop management plans, which include monitoring of laboratory data, to assess clinical outcomes</li> </ul>
1305-1335	<b>Case session: Infectious diseases</b>
1335-1345	BREAK
1345-1515	<b>Case session: Myocardial infarction and heart failure</b>
1515-1530	BREAK

1530-1600	<p><b>Case session: Coagulation</b></p> <ul style="list-style-type: none"> <li>• Use laboratory data to assess the appropriateness of drug therapy for clinical case scenarios</li> <li>• Develop management plans, which include monitoring of laboratory data, to assess clinical outcomes</li> </ul>
1600-1615	<b>Summary and close</b>
1615-1620	<b>Close of live virtual seminar</b>

*Please note: presentation recordings from the live virtual seminar will not be available.*